Alembic Group Business Overview

The Alembic Group is a diverse conglomerate with a wide range of businesses. It was founded by Jayant Damani in 1993.

Alembic Pharmaceuticals is one of its key business segments, with a global presence in over 40 countries. Its products are available in over 50 countries.

The group's pharmaceutical business has a strong focus on research and development, with a portfolio of over 200 products.

You might enjoy: B Capital

The Alembic Group's business operations are a key part of its success. The company has a strong presence in the Indian pharmaceutical market, with a portfolio of over 1,500 products.

Alembic's manufacturing facilities are located in Vadodara and is equipped with state-of-the-art technology to ensure high-quality products.

Alembic's business operations are supported by a robust supply chain network that enables efficient distribution of products to customers across the country.

A different take: Cassa Centrale Banca - Credito Cooperativo Italiano

The Alembic Group has a diverse presence across various sectors, including pharmaceuticals, chemicals, real estate, engineering, consumer glass, and power generation. Its business operations are spread across multiple companies, each contributing uniquely to its revenue.

Alembic Pharmaceuticals Ltd is a leading Indian pharmaceutical company, specializing in active pharmaceutical ingredients (APIs), formulations, and generics. It reported ₹6,256.90 crore revenue in FY 2024.

The Alembic Group's presence in the chemicals sector is significant, with Paushak Ltd being a key player in producing phosgene-based intermediates for pharmaceuticals, agrochemicals, and performance chemicals. It reported ₹226.80 crore revenue in FY 2024.

Alembic Ltd operates in pharmaceuticals, chemicals, and real estate, and has diversified its portfolio over decades. It reported ₹212.30 crore revenue in FY 2024.

Here's a breakdown of the Alembic Group's sector presence:

The Alembic Group has strategically expanded beyond pharmaceuticals, diversifying into new sectors to strengthen its business portfolio.

Alembic Group has established Bhailal Amin General Hospital (BAGH), a tertiary care multi-specialty hospital in Vadodara. BAGH is the only hospital approved by the state and the central government of India to conduct cardiac treatment, surgery, kidney transplants/surgery and cadaver transplants.

BAGH is a remarkable example of a company's commitment to providing quality healthcare services. Alembic Group's investment in BAGH has made a significant impact on the healthcare landscape in Gujarat.

Here's a brief overview of BAGH's notable services:

BAGH's approval by both the state and central governments of India is a testament to its high standards and expertise in various medical fields.

Alembic Group faces significant challenges across its businesses, including regulatory hurdles, market competition, supply chain disruptions, and evolving industry dynamics.

Regulatory hurdles pose a major challenge, particularly in the pharmaceuticals and chemicals sectors, where strict compliance requirements demand continuous investment in quality control, research, and legal expertise.

Market competition is fierce, with Alembic Group facing off against domestic and international players across its business segments. Price wars, innovation races, and market consolidation make it crucial to differentiate products and strengthen brand positioning.

Supply chain disruptions can have a major impact on operations, with fluctuations in raw material availability, logistics delays, and geopolitical factors all posing risks. To mitigate these risks, Alembic Group must optimize sourcing strategies and invest in alternative supply channels.

Worth a look: Major Medical Companies

Evolving industry dynamics, including rapid technological advancements and changing consumer preferences, also pose a challenge. To stay ahead, Alembic Group must embrace digital transformation, invest in R&D, and explore emerging trends.

Here are the key challenges facing Alembic Group across its businesses:

Alembic Group's financial performance has been impressive, with a revenue of ₹6,256.90 crore in FY 2024. This is a significant increase from its FY 2024 revenue of ₹4,001.10 crore.

The company's net profit has also seen a substantial growth, reaching ₹615.8 crore in FY 2024. This is a notable improvement from its FY 2024 net profit of ₹349.60 crore.

In terms of returns, Alembic Group's stock has delivered strong results, with a 1-year return of -9.90%, a 3-year return of 5.03%, and a 5-year return of 9.14%.

Intriguing read: Boston Consulting Group's Advantage Matrix

The quarterly results of a company are a crucial indicator of its financial performance. In the given data, we can see a significant fluctuation in sales and expenses over the past two years.

Sales have shown a steady increase, with the highest sales recorded in Jun 2025 at Rs. 60 crores.

Expenses have also increased, but at a slower rate than sales. The highest expenses were recorded in Dec 2024 at Rs. 33 crores.

The operating profit margin (OPM) has been steadily improving, with the highest OPM recorded in Mar 2024 at 49%.

Here's a breakdown of the quarterly results:

The company's net profit has also shown a steady increase, with the highest net profit recorded in Sep 2024 at Rs. 121 crores.

Alembic Group reported a revenue of ₹6,256.90 crore in FY 2024, a significant increase from the previous year.

The company's net profit for FY 2024 was ₹615.8 crore, a substantial growth from the previous year's net profit.

Alembic Group's stock delivered strong returns, with a 1-year return of -9.90% and a 3-year return of 5.03%.

The company's dividend yield is 1.31%, indicating a relatively low dividend payout ratio.

Here's a breakdown of Alembic Group's financial performance over the years:

The company's financial performance is a testament to its strong business model and growth strategy.

The Alembic Group's shareholding pattern has remained relatively stable over the years, with promoters holding a significant stake.

As of December 2024, promoters held 70.88% of the company's shares, a figure that has remained constant since March 2023.

The company has seen a slight increase in public shareholding, with the percentage rising to 27.68% by September 2025.

The shareholding pattern of a company is a crucial aspect of its governance, and it's essential to understand who holds the majority of the shares. This can impact the company's decision-making processes and ultimately, its performance.

Promoters hold a significant stake in the company, with a consistent 70.88% shareholding from Dec 2022 to Sep 2025. This suggests a high level of control and influence over the company's operations.

The number of shareholders has fluctuated over time, with 83,630 shareholders in Dec 2022 and 1,06,470 shareholders in Sep 2025.

Here's a breakdown of the shareholding pattern over time:

The shareholding pattern has remained relatively stable over the past few years, with promoters holding a consistent majority stake.

The leadership at Alembic Ltd is comprised of experienced individuals who have been with the company for decades. Chirayu Amin, the Chairman, has been with the company since 1967.

Mr. Amin holds an M.B.A. from the U.S.A. and has held various leadership roles in organizations such as FICCI-New Delhi and the International Chamber of Commerce (India Chapter).

Malika Amin, the Managing Director and CEO, joined the organization in 1988 and boasts over 30 years of expertise in managing business strategy, administration, and human resources.

She holds a Master of Arts degree and has been a key figure in the company's consistent sales growth amid tough competition in the pharmaceutical industry.

Here is a brief overview of the key personnel at Alembic Ltd:

Alembic Group is focusing on innovation to drive long-term success, with a strong emphasis on research and development to introduce advanced formulations and high-value products.

The company is investing heavily in R&D to maintain a competitive edge and meet evolving industry demands. This includes expanding its R&D capabilities to introduce advanced formulations, specialty chemicals, and high-value products.

Suggestion: Bharatpe Value

Alembic Group is also actively enhancing its presence in international markets, particularly in the U.S., Europe, and emerging economies. Strategic acquisitions, regulatory approvals, and partnerships will drive geographical diversification and revenue growth.

To achieve sustainability and reduce its carbon footprint, Alembic Group is adopting eco-friendly manufacturing practices and ensuring compliance with environmental regulations. This will help in long-term cost efficiency and align with global ESG (Environmental, Social, and Governance) standards.

The company is also integrating advanced digital solutions, AI-driven analytics, and automation across its operations to improve efficiency, enhance decision-making, and optimize production and supply chain management for future growth.

Here are some key areas of focus for Alembic Group's growth and strategy:

* Innovation and R&D Investment:

+ Expanding R&D capabilities to introduce advanced formulations and high-value products

+ Investing in research to maintain a competitive edge and meet evolving industry demands

* Global Expansion:

+ Enhancing presence in international markets, particularly in the U.S., Europe, and emerging economies

+ Strategic acquisitions, regulatory approvals, and partnerships to drive geographical diversification and revenue growth

* Sustainability and Green Initiatives:

+ Adopting eco-friendly manufacturing practices to reduce carbon footprint

+ Ensuring compliance with environmental regulations for long-term cost efficiency and alignment with global ESG standards

* Digital Transformation and Automation:

+ Integrating advanced digital solutions, AI-driven analytics, and automation to improve efficiency and enhance decision-making

+ Optimizing production and supply chain management for future growth

For your interest: Ubs Mergers and Acquisitions

Investing in Alembic Group stock is a straightforward process. You can easily invest through Alice Blue, where purchasing stocks is absolutely free with zero brokerage on equity delivery trades.

If you're new to investing, you might want to take some time to get familiar with the platform. Use the search bar to find Alembic Group shares.

Before making a decision, it's a good idea to check the market price, charts, and company details. This will give you a better understanding of the stock's performance and potential growth.

To get started, simply use the search bar to find Alembic Group shares on the Alice Blue platform.